

Attorney Docket No.: 5472.210-US

PATENT



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**10/28/99**

**EXPRESS MAIL CERTIFICATE**

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application for  
Title: Injection Syringe  
Applicants: Steenfeldt-Jensen et al.



Sir:

Express Mail Label No. EL293690907US

Date of Deposit : October 28, 1999

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. 5 Sheets of Formal Drawings
6. Information Disclosure Statement
7. Form PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Gina Maldonado

(Name of person mailing paper(s) or fee)

Gina Maldonado

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123

Attorney Docket No.: 5472.210-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/28/99

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. EL293690907US  
Date of Deposit October 28, 1999



Sir:

This is a request for filing a **continuation** application under 37 C.F.R. 1.53(b) of

Applicants: Steenfeldt-Jensen et al.

Title: Injection Syringe

21 pages of specification 5 sheets of drawings

2 sheets of Declaration and Power of Attorney

The filing fee is calculated as follows:

Basic Fee: \$760.00

Total Claims:  $8 - 20 = 0 \times 18 =$  \$0

Independent Claims:  $1 - 3 = 0 \times 78 =$  \$0

Total Fee: \$760.00

Priority of Danish application no. PA 1998 00130 filed on January 30, 1998 is claimed under 35 U.S.C. 119. A certified copy was submitted with USSN 09/238,849.

Priority of U.S. provisional application no. 60/073,820 filed on February 5, 1998 is claimed under 35 U.S.C. 119.

The benefit of application no. 09/238,849 filed on January 28, 1999 in the U.S. is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$760, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,



Date: October 28, 1999

Steve T. Zelson, Reg. No. 30,335  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123